摘要来源： 试验。 2022 Jun 6; 23（1）：472。 EPUB 2022 6月6日。PMID： 35668500 Sahebkar, Davood Soleimani, Atena Mahdavi, Sahar Rafiee, Muhammed Majeed, Farzin Khorvash, Bijan Iraj, Mahshid Elyasi, Mohammad Hossein Rouhani, Mohammad Bagherniya Gholamreza Askari 背景： covid-19流行学院通过对Healt造成重大负担，使该疾病成为一个主要的全球问题H，经济和社会地位。迄今为止，该疾病还没有有效和批准的药物。姜黄素作为抗炎剂可以对COVID-19并发症的控制产生积极影响。这项研究旨在评估姜黄素 - 二哌氨致补充剂对临床症状，持续时间，严重程度和炎症因素的功效。姜黄素粉蛋白；每个胶囊含有500 mg姜黄素加5毫克的杂氨酸或安慰剂14天。 结果： 平均全部血液计数的变化，肝酶，血糖水平，脂肪参数，脂肪剂，儿童功能和c-Rectlying（cr），criptive noundery（crigant）互为差异。健康状况有显着改善，包括干咳嗽，痰液Coug在姜黄素粉皮和安慰剂组的第2周，H，Ag，Ague，Ague，喉咙痛，无力，肌肉疼痛，头痛和呼吸困难（P值<0.05）； however, the improvement in weakness was more in the curcumin-piperine group than with placebo group (P value 025). CONCLUSION: The present study results showed that curcumin-piperine co-supplementation in outpatients with COVID-19 could significantly reduce weakness. However, in this study, curcumin-piperine co-supplementation could not significantly affect the other indices, including biochemical and clinical indices. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20121216011763N46 . 2020-10-31。